Etoposide is one of the most widely used antineoplastics. Unfortunately, the same treatment schedules associated with impressive efficacy are associated with an increased risk of secondary acute myeloid leukemia (AML), which has prompted its withdrawal from some treatment regimens, thereby potentially compromising efficacy against the original tumor. Because etoposide-associated AML is characterized by site-specific illegitimate DNA recombination, we studied whether etoposide could directly cause site-specific deletions of exons 2 and 3 in the hprtgene. Human lymphoid CCRF-CEM cells were treated with etoposide for 4 hours, and DNA was isolated after subculturing. The deletion of exons 2 and 3 from hprtwas assayed by a quantitative polymerase chain reaction (PCRI method. In the absence of etoposide treatment, the frequency of deletions of exons 2 and 3 was very low (5.05 x 10"'). After exposure t o 10 p m o l l L etoposide, the frequency of the exon 2+3 deletion was increased immediately after and at 24 hours after etoposide HE EPIPODOPHYLLOTOXINS, etoposide and teniposide, are among the most widely used and broadly efficacious anticancer drugs in clinical use.' However, their use has been associated with a devastating toxicity, ie, secondary acute myeloid leukemia (AML).'" Epipodophyllotoxin-associated AML is characterized by unique clinical and biologic features. Compared with alkylator-associated secondary AML, the latency period is shorter, the phenotype is usually M4 or MS rather than M6 or M7, the myelodysplastic prodrome phase is absent, and the myeloid blasts are characterized by balanced chromosomal translocations involving 1 1q23.3.7*8 Sequencing of the translocation breakpoints has shown site-specificity in rearrangements of the M U (or ALL-l) gene on 1 lq23 and its numerous partner gene^,^"^ including topoisomerase I1 cleavage sites,'-'' AZu repeats,''.l6 X-like elements," and V(D)J recombination recognition signal sequences." Although the precise mechanism and sequence of events is not known, it appears that sitespecific DNA rearrangement processes may be involved in the leukemogenic transforming events leading to epipodophyllotoxin-associated AML.
treatment (65 t o 89 x IO-') and increased t o higher levels (128 t o 173 x IO-') after 2 and 6 days of subculture (P< .W1 overall). The frequency of the exon 2+3 deletion assessed at 6 days of subculture after 4 hours of 0, 0.25. 1, 2.5, 5, and 10 pmollL etoposide treatment increased with etoposide concentration, ie, 5.05 x IO-', 89.2 x IO-', 108 x IO-', 142 x IO-', 163 x IO-', and 173 x IO-', respectively ( P < .0001). Sequencing of a subset of amplified products confirmed the presence of DNA sequences at the breakpoints consistent with V(D)J recombination. By contrast, exon 2+3 deletions after etoposide treatment in the myeloid cell lines KG-1A and K562 showed no evidence of V(D)J recombinase in their genesis. We conclude that etoposide can induce the illegitimate site-specific action of V(D)J recombinase on an unnatural DNA substrate after a single treatment in human lymphoid cells. 0 1996 b y The American Society of Hematology.
the leukemogenic transforming events leading to epipodophyllotoxin-associated AML.
The epipodophyllotoxins are known mutagens, causing point mutations, small and large deletions, and insertion^.'^"^ Using an extrachromosomal shuttle vector, it has been shown that teniposide interferes with DNA recombination in COS 1 cells.'" The epipodophyllotoxins are potent inhibitors of topoisomerase 11, preventing the religation of double-stranded DNA by forming a stable ternary complex with topoisomerase I1 and DNA.2'.zz This inhibition of normal DNA strand passage via topoisomerase I1 is associated with a host of DNA-damaging responsesz3 and could result in the enhancement of inappropriate methods of DNA re~ombination.'~ The process normally responsible for T-cell receptor and Ig gene rearrangement in lymphocytes, collectively termed V(D)J recombination, involves at least four distinct steps that conclude by coupling a variety of different gene segments, thus resulting in DNA rec~mbination.~~ V(D)J recombination has been shown to be involved in the genesis of a number of lymphoid malignancies, with unnatural genes serving as substrates, apparently at least partly by virtue of the presence of V(D)J recognition heptamer and nonamer signal sequences.'' Thus, it appears that illegitimate activity of V(D)J recombinase is one mechanism of mammalian DNA recombination that can contribute to malignant transformation. However, as important (and more relevant to the current work) is that inappropriate or increased V(D)J recombination could serve as an indicator that the cell has resorted to extreme (ie, inappropriate site-specific) mechanisms of DNA recombination, thereby serving as a biomarker for inappropriate recombination or genetic instability.
It has been shown that illegitimate V(D)J recombination can be induced by xenobiotics, eg, in vitro using an extrachromosomal shuttle vector and caffeine exposure:6 in vivo in lymphocytes of workers exposed to pesticides?' in lymphocytes of patients receiving multiagent cytotoxic chemotherapy:' and ex vivo in cultured lymphocytes exposed to l-nitroso~yrene.'~ The latter examples have the advantage that recombination was assessed in endogenous genes in Blood, Vol 88, No 6 (September 19, 1996 : pp 2210- 2218 For personal use only. on December 24, 2017 . by guest www.bloodjournal.org From their normal chromatin structure. Deletion of exons 2 and 3 of hprt in intact cells is mediated by the illegitimate action of V(D)J re~ombinase,2~.~~ which could serve as an indicator of nontransforming nonhomologous DNA recombination. We reasoned that the pharmacologic actions of etoposide, in which DNA religation is severely inhibited through its complexing with topoisomerase 11, might result in induction of the illegitimate activity of V(D)J recombinase in a fraction of the cells that survive treatment, thereby resulting in sitespecific nonhomologous recombination. We therefore investigated this previously untested hypothesis in human leukemic cell lines.
MATERIALS AND METHODS

Materials.
Etoposide was a gift of Bristol (Syracuse, NY). hprt primer A106 (5'-CTACTGCCCTCTTACATGAGACAC, 22718-22741), primer A107 (5'-CAGTTTCCCGGGTTCGG, 1835-1851), and primer AI 15 (5'-GTGCGATGGTGAGGTTCT, 2094-21 1 l) were purchased from Biosynthesis Inc (Lewisville, TX). The probe A217 (5'-TGGGGACCAGGl"GCCT, 2166-2185) was obtained from Operon (Alameda, CA). Nucleotide numbering for the hprt gene was per Edwards et al." The primers A106, A107, and A1 15 were unpurified; primer A217 was purified by high-performance liquid chromatography (HPLC). Tris base, 2-mercaptoethanol, Ficoll 400, human placenta genomic DNA, and other related chemicals were purchased from Sigma (St Louis, MO). Nucleotides (dATP, dTTP, dCTP, and dGTP) were from Pharmacia Biotech (Piscataway, NJ). Taq DNA polymerase was from Perkin-Elmer (Norwalk, CT). Nusieve (3:l) agarose was from FMC (Rockland, ME). The 123 DNA ladder and BamHI were from GIBCO BRL (Gaithersburg, MD). [(Y'~P]~ATP and 5"labeling kit were from Amersham (Arlington Heights, L). Calf thymus DNA was from Hoefer Scientific Instruments (San Francisco, CA). Polymerase chain reaction (PCR) water from Promega (Madison, WI) was used in all PCR reactions. DNA extraction kits were from Qiagen Inc (Chatsworth, CA). Quick Spin G-25 Sephadex columns for purification of radiolabeled DNA were from Boehringer Mannheim (Indianapolis, IN). Cell culture medium (RPMI 1640) and L-glutamine were from BioWhittaker (Walkersville, MD). Fetal bovine serum (FBS) was from Falcon (Lincoln Park, NJ) and heated at 56°C for 30 minutes before use. An OminiGene Hybaid temperature cycler (Model TR3 SM2; Woodbridge, NJ) was used throughout. The TKO 100 minifluorometer used for determination of DNA was from Hoefer (San Francisco, CA). The Slide-A-Lyzer dialysis cassettes were purchased from Pierce Chemical CO (Rockford, IL). GeneScreen Plus' hybridization transfer membranes were from E.I. du Pont de Nemours & CO (Boston, MA).
Cell lines and culture. Human lymphoid leukemia (CCRF-CEM) and myeloid (KG-IA, promyeloblastic, and K562, multipotential myelocytic) cells were purchased from ATCC (Rockville, MD). CEM and K562 cells were propagated in RPMI 1640 supplemented with heat-inactivated FBS 10% (voUvol) and 2 mmoVL Lglutamine at 37°C in 95% air/5% CO,. Iscove's modified Dulbecco's medium plus 20% heat-inactivated FBS was used as culture medium for KG-l A. Cell counts were performed manually by hemacytometer using trypan blue exclusion as the criterion for viability.
Preparation ofpositive controlplasmid DNA. DNA from mutant MM30M9" was amplified using primers A106 and A107. The amplification product spans the 20-kb V(D)J recombinase-mediated deletion and was ligated directly into TA Cloning vector pCR I1 by using the TA Cloning kit (Invitrogen, San Diego, CA). Plasmid DNA was extracted using the Qiagen Plasmid kit, linearized by BamHI digestion, purified using the QIAquick Gel Extraction Kit, dialyzed, quantitated using Hoechst 33258 and fluorometry with plasmid pBR322 as the standard, and used as a positive control throughout these studies.
Determination of toxicity of etoposide against CEM cells. Etoposide was prepared in dimethylsulfoxide (DMSO), the final concentration of which was always 0.1%, which had no effect on cell growth. CEM cells in logarithmic-phase at 1 X IO6 cells/mL were treated with 0, 0.25, 1.0, 2.5,5, or 10 pmoVL etoposide for 4 hours; washed with drug-free medium twice; and subcultured to a density of 3 X 1 05/mL every 2 days. CEM cells were collected immediately after 4 hours of treatment and after 1, 2, and 6 days for extraction of genomic DNA. Each time/concentration assessment was performed in duplicate in two independent experiments. Cytotoxicity was estimated as 1 -the ratio of cell numbers in treated versus control cells. IC5,, (the concentration producing 50% inhibition of cell growth relative to untreated control cells) for a given duration of exposure was estimated using nonlinear least squares regression (MINSQ; MicroMath, Salt Lake City, UT) and the sigmoid E, , model: % cytotoxicity = 100 X ConcY/ + ConcY).
Determination of toxicity of etoposide against myeloid cells. KG-1A and K562 cells were treated exactly as were CEM cells, except that etoposide concentrations ranged from 1 to 100 and from 5 to 100 pmoVL, respectively.
Preparation and determination of genomic DNA. DNA was prepared using the Qiagen Blood & Cell Culture DNA kit, dissolved in 10 mmoVL Tris-HC1 (pH 8.0)-1 mmoVL EDTA (TE), dialyzed against TE, and concentrated (if necessary) using Centricon-IO columns (Amicon, Beverly, MA). The concentration of DNA was determined by fluorometry using calf thymus DNA for standards.
Detection of the exon 2+3 hprt deletion. A heminested PCR was performed using modifications of previously described procehprt, the majority of which were previously shown to be due to the illegitimate action of V(D)J recombinase." Round 1 reactions contained 67 m m o K Tris-HC1 (pH 8.8). 6.7 mmoVL MgCI,, 16.6 mmoVL ( m ) 2 S 0 4 , 5 mmoVL 2-mercaptoethanol, 6.8 pmoVL EDTA, 0.75 mmoVL each dNTP, 10% DMSO, 0.075 pmoVL each of primers A106 and A107, 2.5 pg DNA, and water to bring the volume to 47.5 pL. The final TE concentration (0% to 45% voUvol) in the PCR reactions did not affect the efficiency of amplification of positive control DNA. Fifty microliters of light mineral oil was layered on top. After 3 minutes at 80°C. 2.5 U of Taq DNA polymerase (1 U/pL) was added (hot start). The PCR conditions were denaturation (94°C for 4 minutes) followed by 40 cycles of 94°C for 1 minute, 59°C for 1 minute, and 68°C for 2 minutes, with a final extension of 68°C for 5 minutes. Round 2 reactions contained 10 mmom Tris-HC1 (pH 8.3), 50 mmoVL KCl, 0.1% gelatin, 3 mmoU L MgC12, 0.2 mmoVL each dNTP, 0.2 pmoVL each of primers A106 and A115, 2.5% Ficoll, 0.005% xylene cyanole FF, 2.5 U of Taq DNA polymerase, and water to bring the volume to 49 pL. Fifty microliters of mineral oil was layered on top and 1 pL of the PCR product from the first-round PCR was added. The PCR conditions were the same as for the first round except that 20 cycles were performed; the extension temperature was 72"C, with no hot start. Positive control reactions consisted of linearized plasmid DNA plus 2.5 pg human placenta DNA. Negative controls had water replacing genomic DNA. At least one positive control and 10 negative control reactions were included in each PCR run.
Twenty microliters of each PCR reaction was electrophoresed through a 2.5% NuSieve (3:l) agarose gel in TBE. After ethidium bromide staining and UV visualization, the gels were treated with 250 mN HCI for 15 minutes, followed by 0.4 N NaOH/0.6 m o m NaCl for 30 minutes. DNA was transferred to Genescreen Plus nylon membranes in 0.4 N NaOW0.6 m o m NaCl over 12 hours, which were baked at 80°C in vacuum for 2 hours and prehybridized dures30.32.33 to detect and quantify the deletion of exons 2 and 3 of
For personal use only. on December 24, 2017. by guest www.bloodjournal.org From for 4 hours with 5 X SSPE, 0.25% dried skim milk, and 100 wg/mL denatured salmon sperm DNA. Hybridization to "P-labeled A217 probe was performed at 42°C in 5 X SSPE, 2% sodium dodecyl sulfate (SDS), 10% dextran sulfate, and 100 FglmL salmon sperm DNA for 4 hours. The membrane was washed in 2X SSC and then in 0.1% SDS/2X SSC at 42°C for 30 minutes each, exposed to Storage Phosphor Screens, scanned in the Phosphorlmager, and visualized by SpotFinder (Molecular Dynamics, Sunnyvale, CA). The most common class of V(D)J recombinase-mediated deletions results in a fragment of approximately 595 bp with these primers.'"
Quantiration of the frequency of the exon 2+3 deletion. At least 10 replicates of 2.5 pg DNA each were assayed for each sample. The fraction of replicates per sample that was negative for hprtspecific PCR products was determined. The frequency of the hprr exon 2+3 deletion mutants in the cell samples was estimated using
Poisson statistic^:^ assuming that each cell contained 6.25 pg DNA and that the PCR reaction was able to amplify a single copy of the exon 2+3 deletion in 2.5 pg of cellular genomic DNA. The average number of deletion junctionslPCR reaction, x, was estimated from P,, the fraction of PCR reactions with no deletion junction using the relationship P, = e-". The average DNA content per cell was assessed by direct fluorometric assay of sonically disrupted known numbers of untreated (n = 17 replicates) and etoposide-treated cells (n = 60 replicates), and the average (SD) DNA content per cell was 6.37 t 0.37 v 6.52 f 0.74 ( P = .22) in the untreated versus treated cells, respectively. Thus, the DNA content per cell was assumed to be constant in all experiments.
Sequencing of hprt exon 2+3 deletionjunctions. The heminested PCR was performed. Several PCR products, each one obtained from different experiments, were separated on gels, purified with QIAquick Gel Extraction Kits, and sequenced using the cycle sequencing reaction employing fluorescence-tagged dye terminator ( 
(A/G)N(T/C)NNCNNG(T/C)NG(G/T)TN(T/C)N(T/C)I3" and [AC(G/A)T(G/A)CGCGCG(C/T)A(C/T)GT],"7 and topoisomerase I cleavage site consensus sequences [(C/G)?T]" were analyzed.
Staristical analysis. The exact Wilcoxon rank-sum test was used for testing whether there was a trend in the proportion of null replicates versus time or concentration. The x ' test was used to verify that the observed frequency of the proportion of null replicates in the positive controls was not different from that expected.
RESULTS
Validation of the PCR method. DNA from untreated CEM cells from all experiments failed to yield amplified product in 196 of 200 replicates, a frequency that was not higher than that observed using water alone (98 of 100) without genomic DNA ( P = 1 .0). Human placental genomic DNA also failed to yield amplified product at a significant level. To determine the sensitivity of the method, various amounts of the linearized positive contrd plasmid DNA (representing an average of 0.075,0.15, 0.75, and 2.7 copies per replicate) were diluted in 2.5 pg human placental genomic DNA as indicated in Table I . There was no difference in the observed versus the predicted frequency of the exon 2+3 deletion ( P = .837), indicating that the procedure was sufficiently sensitive to detect 1 mutant per reaction. Linearized plasmid DNA contains 4.77 kb. The molecular weight of genomic DNA was assumed to be 1.91 x 10''. Thus, 2.5 @g of genomic DNA was assumed to be equivalent to 1.31 x 10-9pmol. The numbers in parentheses indicate the number of null/number oftested replicates at each positive control concentration.
Abbreviations: X, average number of deletion junctiondPCR reaction; Po, fraction of PCR reactions with no deletion junction and Po = e-x.
Poisson statistics predict that, when an average of 2.7 copies of the exon 2+3 deletion are present in the PCRs, 93% of replicates should contain at least 1 copy of the exon 2+3 deletion DNA and therefore generate a specific PCR product. Thirty-six of 40 (90%) replicates (95% confidence interval [CI], 76.3% to 97.2%) containing an average of 2.7 copies of the linearized positive control DNA diluted in 2.5 pg of placental DNA yielded a specific PCR product, in good agreement with the expected value. Thus, this amount (2.7 X ng of plasmid DNA) was used in routine positive control samples. The extreme sensitivity of this PCR method dictates that multiple negative controls are run with each experiment. Using water as the negative control, only 2 of 100 replicates showed contamination with the exon 2+3 deletion, which thus represents the baseline frequency of the exon 2+3 deletion in our experiments.
The effects of dialysis on the amplification of substrate DNA were evaluated by dividing DNA samples from etoposide-treated CEM cells into two aliquots: one was dialyzed against TE at room temperature for 24 hours and the other was not. Amplification of the exon 2+3 deletion mutant was more frequent in two dialyzed samples (3 of 10 and 5 of 10) than in the same two samples that were not dialyzed before amplification (0 of 10 and 0 of IO, respectively; P = .002). Therefore, all DNA samples used for quantitating the hprt exon 2+3 deletion were dialyzed before DNA quantification by fluorometry and use in PCR.
E#ects of etoposide on exon 2+3 deletion frequency in CEMs. The average (SD) etoposide IC5" determined after 4 hours of exposure in CEM cells assessed after 2 and 6 days of subculture was 1.26 (0.089) pmoVL and 0.65 (0.047) pmol/L, respectively (Fig 1) .
In 200 replicates of untreated CEM cells representing 4 X los cells each, only 4 (2%) yielded detectable hprt exon 2+3 deletions. This low level (5.05 X lo-*) of hprt exon 2+3 deletions is identical to that observed in negative control water replicates and was used as the baseline frequency (ie, no etoposide treatment) in both the time-course and concentration-dependence comparisons. Using 10 ,umol/L etoposide for 4 hours, the frequency of exon 2+3 deletions increased from pretreatment to day 6 ( P < .001), although there was no significant change in the frequency between days 2 and 6 of subculture (P = .418; Fig 2) . These data suggest that there was minimal growth advantage or disadvantage caused by the hprr exon 2+3 deletion and that 2 to 6 days of subculture is an informative mutation expression period after etoposide treatment.
The frequency of deletions was dependent on the etoposide concentration (P < .OO01; Fig 3) . A typical Southern blot depicting treated versus untreated cells is shown in Fig  4. These data indicate that, even at etoposide concentrations near the ICso, the frequency of hprt exon 2+3 deletions is significantly higher than baseline at approximately 1 per 1 X lo6 cells. Sequencing of hprt exon 2+3 deletions in CEMs. Of all the CEM cell replicates tested in these experiments, a total of 110 replicates were positive for hprt exon 2+3 deletions; of these, all except 1 (ie, total of 109) yielded a PCR product of approximately 595 bp, the size predicted to be the most common based on previous sequencing of individual exon 2+3 deletion clones from normal infants' lymphocyte^.^' We amplified and sequenced 10 separate 595-bp PCR products from CEM cells treated with etoposide from several independent experiments. We identified 5 different patterns of deletion sequences. In all cases, the localization of the 5' breakpoint of the mutation was between nucleotides 2191 and 2197 of hprt intron 1, immediately preceding a consensus V(D)J recombinase heptamer sequence (Fig 5) . Moreover, in all cases, the 3' breakpoint was at 22250-22251 in intron 3, immediately 3' to V(D)J recombinase heptamer and nonamer consensus sequences in hprt. Nine of the 10 PCRs yielded pure sequences, and 1 yielded a mixture of two sequences. Three different PCRs yielded sequences identical to mutant A, 4 PCRs yielded sequences identical to mutant B, 2 yielded mutants containing N-nucleotide insertions (mutations C and CE106), and the PCR that yielded two sequences had one mutant identical to mutant B and another with a different set of insertions (CE431). There were no topoisomerase I cleavage site sequences or X-like elements in the vicinity of the breakpoints of mutants A, B, C, CE106, and CE43 1. The only topoisomerase I1 consensus sequences36 were located at 2177-2 194 (16/18 matches) and 2209-2226 (W18 matches) in intron 1 and at 22,226-22,243 (16118 matches) in intron 3 (Fig 5) . There were no teniposide-associated topoisomerase I1 cleavage recognition sites3' near the breakpoints.
One of the 110 positive PCR replicates from treated CEMs yielded a smaller sized fragment (450 bp) that hybridized with the hprt-specific probe (A217). The breakpoints were 
QI
-595 bp -595 bp localized at nucleotide 2229 of hprt intron 1 and at position 22429 of intron 3, resulting in a fragment of 450 bp with no insertions (Fig 6) . In this unusual PCR product, although there is a 5 of 7 match heptamer (CTCATTG) close to the intron 1 breakpoint junction at 2232-2238, there was no consensus with the critical three bases3' closest to the cleavage site, and there were no heptamer or nonamer recognition signal sequences near the intron 3 breakpoint. There were two 15/18 matches to the topoisomerase I1 consensus sequence"' located at 2209-2226 and 22430-22447 of intron 1 and intron 3. respectively.
Exon 2+3 deletions in nonlymphaid cells. The lCsos for etoposide against KG-l A and K562 cells were 7.0 pmol/L (95% Cl, 5.8 to 8.1 pmol/L) and 2.5 pmol/L (1.7 to 3.3 pmol/L), which are higher than that obtained in CEM cells, as expected. In KG-l A cells, the frequency of the exon 2+3 deletion was not detectable in untreated and 6.7 X IO-" among all treated replicates tested; the single HPRT-hybridizable product was only 180 bp in length. In K562 cells, the frequency of the exon 2+3 deletion was 4.4 X IO-' in untreated and 2.7 X IO" among all treated cells. Of 68 replicates tested, 7 PCR products were observed, all at the higher etoposide concentrations of 60 to 100 pmol/L; however, none of the 7 was close to the 595-bp size consistent with the V(D)J recombinase-mediated deletions. Of the two bands for which sequencing data were available, the products were 923 and 981 bp in length (Fig 7) . A 4/7 heptamer match was present near the intron 3 breakpoint in mutation KE645A; however, there were no heptamers present in intron 1. Thus, the sequences at the breakpoints were not consistent with V(D)J recombination. However, there were 15/18 nucleotide matches for topoisomerase I1 cleavage recognition sequences spanning the breakpoints at intron 3 in both KE645A and KE645B and in intron 1 of KE645B.
DISCUSSION
This is the first report of evidence that a clinically used medication, etoposide, can induce site-specific DNA rearrangements that are consistent with the illegitimate action of V(D)J recombinase. Epipodophyllotoxin-induced site-specific DNA rearrangements are of interest because they characterize the MLL gene rearrangements typical of epipodophyllotoxin-induced AML .
We have shown that inappropriate V(D)J recombinase-mediated action on an anomalous substrate, ie, the HPRT gene, provides a quantitative indication of one type of aberrant site-specific recombination process induced as a result of etoposide treatment and that this process could serve as a biomarker for site-specific recombination processes that can result in disruption of essential genes.
V(D)J recombination is the only known mammalian system for strict site-specific DNA rearrangement."'.Jn It has previously been shown in spontaneous mutants cloned from human lymphocytes that deletions of exons 2 and 3 in hprf display evidence of V(D)J recombination in their genesis.?wn.~~.4~ The most common class of exon 2+3 deletions" would be predicted to yield approximately 595-bp products using the procedure described in the current study. These mutants display an invariant intron 1 breakpoint just 5' of the consensus heptamer recognition signal sequences at 2197, consensus heptamers and nonamers at the 3' intron 3 breakpoint, nibbling, non-germline-encoded nucleotides, and P-nucleotides."'~20~"~4' However, in various pre-B-cell lines, over 30% of the coding joints of V(D)J recombinasemediated recombinants lacked insertions; lack of insertions has also been shown in exon 2+3 mutants from spontaneous"' and I-nitrosopyrene-treated human lymphocytes.29
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I I I I I I I I I I I I I I I I I I I I I Thus, it is not entirely unexpected that we observed multiple replicates with deletions adjacent to the heptamer/nonamer recognition signal sequences but without insertions. Moreover, it is possible that etoposide could increase the activity of some components of V(D)J recombination (eg, endonucleolytic cleavage and religation steps) without increasing the addition of nontemplated insertions of nucleotides (eg, by terminal deoxynucleotidyl transferase). After etoposide treatment, the majority of the PCR products we observed (109 of 110 [99%]) yielded the predicted 595-bp PCR product that hybridized with the hp-specific probe. The T and G in the N-nucleotide insertion sequence TGGC/A of mutants C and CE106 are consistent with P-nucleotide addition,"' although it is possible that the T and G nucleotides are the result of nucleotidyltransferase activity43 and only coincidentally match the expected P nucleotides. Although only 10 of the 109 595-bp deletion products we observed in treated CEMs were sequenced, all 10 were consistent with V(D)J recombinase-mediated deletions (Fig 5 and Results) . In contrast, there was no significant evidence that the exon 2+3 deletion in the one PCR product of slightly smaller size (mutation D) was V(D)J-mediated (Fig 6) . This smallersized product was present in less than 1% of all exon 2+3
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deletion PCR products in CEMs we observed. The A + T content is high (88%) at 22389 to 22428 (near the cleavage site of intron 3, mutant D), which has been postulated to predispose to illegitimate recombination." In addition, there was no evidence that V(D)J recombination was etiologic in the exon 2+3 deletion mutants observed in two nonlymphoid cell lines (KG-1A and K562; Fig 7) , consistent with the lack of RAG-l expression in most nonlymphoid lines previously reported.45 It is noteworthy that, in entirely independent experiments, we observed several mutants that were identical to each other. Mutation C , which exhibits both nibbling and insertions, was also obtained in a subsequent independent experiment in which we are cloning CEMs containing the exon 2+3 deletion (data not shown). Such hot spots for hprt deletions and isolation of identically sequenced mutations from independent mutants have previously been reported in pso-2220 l wthtronl ralen-treated human lymphocytes of patients with Fanconi anemia." ' Other sequences that might direct site-specific recombination, such as A h sequences3' or X-like element^,^' were not present in the vicinity of the breakpoints of the typical 595-bp products giving rise to mutations A, B, and C. Although examination of DNA for topoisomerase I1 consensus seq u e n c e~~~.~' either in the rearranged substrate or in the wild-type substrate has limitations and the absence of apparent topoisomerase I1 cleavage sites does not preclude the involvement of topoisomerase I1 in the genesis of rearrangements, we did find slightly mismatched topoisomerase I1 consensus sequences36 ending as close as four nucleotides 5' from the breakpoints in intron 1. Also, alternating G/T stretches, such as (GT),:! present at 22230 to 22253 in hprt, have been reported to preferentially direct topoisomerase 11-mediated DNA cleavage.46 Thus, it is possible that both illegitimate V(D)J recombinase activity and topoisomerase I1 might be involved in causing site-specific deletions in hprt.
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Site-specific DNA rearrangements in CEMs were related to etoposide concentration and occurred at concentrations that are routinely achieved in blood in vivo and near the ICso in vitro.' The frequencies reported cannot be interpreted as true mutation frequencies (the creation of individual mutant clones), because assessments at 6 days could both overestimate (because of clonal expansion of mutants) and underestimate the mutation frequency (because of death of mutants or the presence of more than one mutation in a single PCR, as we showed in l of 10 fragments sequenced). It is not likely that etoposide treatment simply selected for pre-existing hprt exon 2+3 deletion mutants by preferentially killing nonmutant cells, because the deletion frequency was induced after only 4 hours of treatment, at which time no cytotoxicity had occurred. Moreover, the lack of survival advantage or disadvantage of the exon 2+3 deletion-containing cells argues against that hypothesis, and etoposide-treated cells have now undergone more than 20 generations with no change in the deletion frequency (data not shown). Thus, the fact that the deletion frequency was concentration-dependent, present at a very low baseline level (2%) in 200 replicates of untreated CEMs, and invariant from days 2 to 6 indicates that relatively stable clones can be generated with sublethal sitespecific DNA rearrangements as a result of a single etoposide treatment.
The quantitative PCR method used in this report is based on analysis of a binomial response (positive v negative for the deletion) and the assumption that a single copy of the deletion is amplified if it is present in as many as 4 X 10' cells. The estimate of the deletion frequency is strengthened by assaying multiple replicates and has the disadvantage that it requires a relatively large amount of DNA per sample (25 pg for 10 replicates). However, it differs from dilution-based quantitative PCR techniques in that one is not required to assume that PCR conditions are such that amplification is in the linear range (labor-intensive to show for each individual sample); amplification conditions are permissive enough to amplify a single copy of the deletion if it is present in the sample. Because limiting dilution of the positive control DNA amplified in accordance with the frequency expected based on the assumption that a single copy would amplify (following the Poisson distribution; Table l), the method appears to be reliably quantitative. The method we describe herein differs from most previous assessments of the freFor personal use only. on December 24, 2017. by guest www.bloodjournal.org From quency of exon 2+3 deletions in that, instead of cloning and expanding mutants for subsequent assay by PCR, DNA from a large number of unselected cells (4 X lo6 to 8 X lo7 per experimental point) was amplified and the mutant frequency was determined directly using principles of Poisson statist i c~. ~~ We chose CEM cells as our target tissue because these cells constitutively express RAG140,49 and RAG2,"' genes that can confer normal V(D)J recombination upon otherwise negative cells (eg, fib rob last^).^',^' Moreover, CEMs are capable of Ig and T-cell receptor gene rearrangements, the normal function of V(D)J recombinase. It is intriguing that etoposide so readily increases the frequency of V(D)J recombination in a lymphoid cell line, although secondary lymphoblastic leukemias have only rarely been reported after etoposide (reviewed in Hunger et a15' ). Because the same etoposide regimens associated with an increased risk of secondary AML are also associated with better efficacy against the original lymphoblastic leukemia one could speculate that, in vivo, etoposide is more effective against emerging secondary ALL clones than it is against the mutagenized myeloid precursor, thereby permitting manifestation of secondary AML. We did not observe any increase in V(D)J recombinase-mediated deletions in the two myeloid cell lines treated with etoposide, consistent with the findings that myeloid lines are much less likely than lymphoid lines to affect V(D)J re~ombination.~~ Because etoposide's leukemogenic effects most commonly result in a myeloid leukemia, one might argue that increased recombination in lymphoid cells (ie, CEMs) is of little relevance to development of secondary AML. However, it is possible that the sitespecific recombination critical for producing the transformed phenotype occurs only in more primitive cells than could be readily cultured. In any case, our primary interest is to establish a biomarker for etoposide's undesired recombinogenic effects in an accessible tissue, and the tissue type in which that effect is measured may not necessarily be a tissue type capable of differentiating into the monoblastic phenotype most commonly associated with etoposide-induced AML.
Given the ease with which a single etoposide treatment was able to induce a highly regulated system [V(D)J recombination] to inappropriately delete DNA, it is not surprising that repeated etoposide doses, particularly in the context of other anticancer drugs, could result in a transforming DNA rearrangement in the clinical setting. Because the same dosage schedules associated with a higher risk of secondary AML also result in improved efficacy against the original leukemia: the challenge is to elucidate less leukemogenic schedules of etoposide without compromising cytotoxic efficacy. The present study establishes a quantitative method for assessing site-specific recombination that may provide a means of assessing the relevant mutagenic effects of etoposide in vitro and in vivo.
